Sanofi's Kumar On Drug Pricing And US Election Rhetoric
This article was originally published in Scrip
Suresh Kumar, member of Sanofi's executive committee and executive vice president, external affairs, says that part of the high octane discussion in the US around drug pricing in the run up to the presidential election is "populist" but there's another part that stakeholders need to address.
You may also be interested in...
Gland Pharma, controlled by Chinese group Fosun, makes shining debut on Indian stock markets despite a lukewarm response to its IPO. Will the buoyant market sentiment sustain amid edgy India-China relations?
A senior executive of Janssen’s supply chain leadership team outlines how the company handled activities in Asia Pacific at the height of the coronavirus outbreak, including ensuring continuous and rapid supplies of critical medicines in China. The company is also prepping against “multiple scenarios” to ensure global access for its potential COVID-19 vaccine.
Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.